Abbott Labs (ABT) is expected to report Q4 earnings before the market open on Wednesday, January 27, with a conference call scheduled for 9:00 am ET.
GuidanceThe consensus estimate is $1.17 for EPS and $8.59B for revenue, according to First Call. On October 14, Abbott raised its FY09 EPS outlook to $3.70-$3.72 from $3.65-$3.70. Positive drivers for this quarters results may come from strength in Humira and the new Xience stent. The drug giants global diagnostics business may also help drive revenues. Negatives for Abbot in Q4 continue to be generic erosion in drugs like Depakote.
Analyst ViewsIn December, Abbott Labs was removed from the Conviction Buy List at Goldman citing relative valuation for the removal. Shares of Abbott remain Buy rated at Goldman with a $60 price target.
No comments:
Post a Comment